ctDNA动态识别了用尼沃卢马布/雷拉利马布治疗的转移性黑色素瘤患者的伪进展
Alyssa K Steimle1, Steve Y Cho2, Nandakumar Menon2
1Department of Medicine, University of Wisconsin-Madison, Madison, WI.
Journal of immunotherapy (Hagerstown, Md. : 1997)
|July 9, 2025
概括
在转移性黑色素瘤患者中,循环瘤DNA (ctDNA) 可以帮助区分伪进展与真正进展,这些患者接受了免疫检查点抑制剂治疗. 这种生物标志物在成像不清晰时有望评估治疗反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 伪进展使得接受免疫检查点抑制剂的转移性黑色素瘤患者的治疗决策复杂化.
- 准确评估治疗反应对于有效的临床管理至关重要.
研究的目的:
- 为了研究循环瘤DNA (ctDNA) 在识别伪进展中的实用性.
- 评估ctDNA作为转移性黑色素瘤治疗组合免疫治疗的响应评估的生物标志物.
主要方法:
- 病例报告详细介绍了接受抗PD-1和抗LAG-3治疗的转移性黑色素瘤患者.
- 分析循环瘤DNA (ctDNA) 水平,并进行放射性评估.
主要成果:
- 循环瘤DNA (ctDNA) 在识别伪进展方面表现出潜力.
- 当放射学发现不确定时,ctDNA提供了可靠的反应评估.
结论:
- 循环瘤DNA (ctDNA) 是评估黑色素瘤免疫检查点抑制剂反应的有希望的生物标志物.
- 需要进行进一步的研究,以确定在不同免疫疗法方案中检测伪进展的ctDNA动态.
相关概念视频
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K